Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
RMD Open 2025;11:e005969 Doi: 10.1136/rmdopen-2025-005969
Ramiro et al. show that bimekizumab (BKZ) reduces enthesitis and peripheral arthritis in patients with nr-axSpA and r-axSpA up to 2 years. Authors assessed the effect of BKZ treatment on the main peripheral manifestations of axSpA, including enthesitis and peripheral arthritis, using a range of measures including DAPSA, to Week 104 in the BE MOBILE 1 and 2 studies.
Given the high prevalence of enthesitis and peripheral arthritis in axSpA and their impact on the physical functioning and quality of life of patients, these data provide physicians with further evidence for the long-term effect of BKZ on peripheral manifestations of axSpA.
Keywords:
